Abeona Therapeutics Inc. · NASDAQ:ABEO

Abeona Therapeutics — Corporate Update (April 2025)

22 slides from Abeona Therapeutics's corporate update, Apr 29, 2025

  1. Slide 1: ZEVASKYN U.S. FDA Approval

    “YR Abe ona: THERAPEUTICS ZEVASKYN™ U.S. FDA Approval April29, 2025

  2. Slide 2: Note regarding forward-looking statements

    Note regarding forward-looking statements This presentation of Abeona Therapeutics inc. (the “Company*} contains certain statements that are forwarc!-looking within the meaning of Section 27A of the Securities Act of 1933, as ‘amended, and Section 21E of the Securities Exchange Act of 1934, as amend

  3. Slide 3: Indication & Important Safety Information

    Indication & Important Safety Information Indication + ZEVASKYNTM (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Important Safety Information Seriou

  4. Slide 4: Today's speakers

    Today’s speakers &£a Vish Seshadri Madhav Vasanthavada Brian Kevany Chief Executive Officer Chief Commercial Officer and Chief Technical Officer & Head of Business Development Chief Scientific Officer Q&A to follow Abeone

  5. Slide 5: Welcome & introduction

    ——— zevaskyn” (prademagene zamikeracel) gene-modified cellular sheets Welcome & introduction Vish Seshadri Chief Executive Officer

  6. Slide 6: Now FDA approved

    NOW FDA APPROVED zevaskyn” (prademagene zamikeracel) gene-modified cellular sheets Indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB)

  7. Slide 7: Noelle's Story

    ‘es TICS d a cure. Noelle's Story ‘© 2025 Abeona Therapeutics Inc. All Rights Reserved.

  8. Slide 8: RDEB causes significant clinical, economic, and humanistic burden

    RDEB causes significant clinical, economic, and humanistic burden Humanistic Large, painful chronic wounds; risk of infection, on s Significant impact on SCC*, extracutaneous quality of life manifestations Tera eal SFO. Poser "SCC =sa cece “ID drama Abeons’

  9. Slide 9: Example RDEB wounds before & after ZEVASKYN treatment

    Example RDEB wounds before & after ZEVASKYN treatment

  10. Slide 10: Phase 3 VIITAL study clinical experience

    Phase 3 VIITAL study clinical experience Wound healing and pain reduction with a single surgical application - evenin tough RDEB wounds * 81% (35/43) of treated wounds achieved 50% or more healing vs 16% (7/43) of control wounds at week 24 Wound: ed at baseline had been open fora Established safety

  11. Slide 11: Commercial opportunity & launch preparation

    ——— zevaskyn” (prademagene zamikeracel) gene-modified cellular sheets Commercial opportunity & launch preparation Madhav Vasanthavada Chief Commercial Officer and Head of Business Development

  12. Slide 12: Strong Bonds Stand the Test of Time

    Strong Bonds Stand the Test of Time

  13. Slide 13: Strong Bonds Stand the Test of Time

    —— zevaskyn™ (prademagene zamikeracel) gene-modified cellular sheets Strong Bonds Stand the Test of Time Geovanna, a ZEVASKYN™ patient at age 8

  14. Slide 14: Geovanna's Story

    Geovanna's Story © 2025 Abeona Therapeutics Inc. All Rights Reserved.

  15. Slide 15: Strong Together Network

    Strong Together Network © Find Support & Connection

  16. Slide 16: ~1,500 ZEVASKYN treatment opportunities

    ~1,500 ZEVASKYN treatment opportunities based on current prevalent pool Value and pricing story resonates with large national and regional payers zevaskyn”™ (prademagene zamikeracel) gene-modified cellular sheets Committed to innovative outcomes-based arrangements with private and public payers Abeo

  17. Slide 17: ZEVASKYN Hospital stay & manufacturing discharge

    ZEVASKYN Hospital stay & manufacturing discharge

  18. Slide 18: Focused on delivering exceptional ZEVASKYN treatment experience for patients

    m Focused on delivering exceptional ZEVASKYN treatment experience for patients oe @ Patient support hub Patient-to-patient communication and engagement Personalized support when ; zevaskyn” you need it Talk to ZEVASKYN patients and (orademagene zamikeracel) (1-855-ABEONA-1) caregivers about their ex

  19. Slide 19: Partnering with EB Centers of Excellence to drive successful ZEVASKYN launch

    Partnering with well-recognized EB Centers of Excellence (COEs) to drive successful ZEVASKYN launch Site activation process ongoing: First activated qualified treatment center (QTC) anticipated approx 3 mos post approval First biopsy anticipated 3Q 2025 First ZEVASKYN treatment anticipated 3Q 2025 a

  20. Slide 20: Commercial manufacturing

  21. Slide 21: Commercial manufacturing for ZEVASKYN

    = Commercial manufacturing for ZEVASKYN™ GMP Commitment Annual maintenance of equipment and facility for quality assurance and compliance fr Supply ramp-up at current GMP facility to match projected initial demand Long Term Expansion ody Production capacity expansion for ZEVASKYN growth Abeone

  22. Slide 22: Patient testimonials from people living with RDEB

    “| amvery happy. This trial changed my life completely.” Guadalupe, living with RDEB “The benefitis | saw healing, compared to other treatment, where I didn't see healing before.” Mohamed, living with RDEB “My kids knowit was a life altering moment, because then their mom was more available. Their m

Abeona Therapeutics — Corporate Update (April 2025) on 6ix